Literature DB >> 12378618

DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line.

Zhao-Chong Zeng1, Guo-Liang Jiang, Guo-Min Wang, Zhao-You Tang, Walter J Curran, George Iliakis.   

Abstract

AIM: To investigate the role of DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma HepG(2) cell lines.
METHODS: Hep G(2) cells were exposed to hyperthermia and irradiation. Hyperthermia was given at 45.5 degrees C. Cell survival was determined by an in vitro clonogenic assay for the cells treated with or without hyperthermia at various time points. DNA DSB rejoining was measured using asymmetric field inversion gel electrophoresis (AFIGE). The DNA-PKcs activities were measured using DNA-PKcs enzyme assay system.
RESULTS: Hyperthermia can significantly enhance irradiation-killing cells. Thermal enhancement ratio as calculated at 10 % survival was 2.02. The difference in radiosensitivity between two treatment modes manifested as a difference in the alpha components and the almost same beta components, which alpha value was considerably higher in the cells of combined radiation and hyperthermia as compared with irradiating cells (1.07 Gy(-1) versus 0.44 Gy(-1)). Survival fraction showed 1 logarithm increase after an 8-hour interval between heat and irradiation, whereas DNA-PKcs activity did not show any recovery. The cells were exposed to heat 5 minutes only, DNA-PKcs activity was inhibited at the nadir, even though the exposure time was lengthened. Whereas the ability of DNA DSB rejoining was inhibited with the increase of the length of hyperthermic time. The repair kinetics of DNA DSB rejoining after treatment with Wortmannin is different from the hyperthermic group due to the striking high slow rejoining component.
CONCLUSION: Determination with the cell extracts and the peptide phosphorylation assay, DNA-PKcs activity was inactivated by heat treatment at 45.5 degrees C, and could not restore. Cell survival is not associated with the DNA-PKcs inactivity after heat. DNA-PKcs is not a unique factor affecting the DNA DSB repair. This suggests that DNA-PKcs do not play a crucial role in the enhancement of cellular radiosensitivity by hyperthermia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378618      PMCID: PMC4656564          DOI: 10.3748/wjg.v8.i5.797

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  53 in total

1.  Progress in research of liver surgery in China.

Authors:  Meng-Chao Wu; Feng Shen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group.

Authors:  H Wang; Z C Zeng; T A Bui; E Sonoda; M Takata; S Takeda; G Iliakis
Journal:  Oncogene       Date:  2001-04-26       Impact factor: 9.867

3.  A DNA double-strand break repair-deficient mutant of CHO cells shows reduced radiosensitization after exposure to hyperthermic temperatures in the plateau phase of growth.

Authors:  G Iliakis; R Seaner
Journal:  Int J Hyperthermia       Date:  1990 Jul-Aug       Impact factor: 3.914

4.  Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.

Authors:  J Fan; Z Q Wu; Z Y Tang; J Zhou; S J Qiu; Z C Ma; X D Zhou; S L Ye
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

5.  Relative rates of homologous and nonhomologous recombination in transfected DNA.

Authors:  D B Roth; J H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

6.  Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy.

Authors:  Yang-Fu Jiang; Zhi-Hua Yang; Jin-Qun Hu
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

7.  Role of DNA-PK subunits in radiosensitization by hyperthermia.

Authors:  E C Woudstra; A W Konings; P A Jeggo; H H Kampinga
Journal:  Radiat Res       Date:  1999-08       Impact factor: 2.841

8.  Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme.

Authors:  P K Sneed; P R Stauffer; M W McDermott; C J Diederich; K R Lamborn; M D Prados; S Chang; K A Weaver; L Spry; M K Malec; S A Lamb; B Voss; R L Davis; W M Wara; D A Larson; T L Phillips; P H Gutin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-15       Impact factor: 7.038

9.  P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.

Authors:  Lun-Xiu Qin; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Xin-Da Zhou; Qing-Hai Ye; Yuan Ji; Li-Wen Huang; Hu-Liang Jia; Hui-Chuan Sun; Lu Wang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

10.  Phase I clinical trial of oral furtulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathologic study.

Authors:  Z C Zeng; Z Y Tang; Z Q Wu; Z C Ma; J Fan; L X Qin; J Zhou; J H Wang; B L Wang; C S Zhong
Journal:  Am J Clin Oncol       Date:  2000-10       Impact factor: 2.339

View more
  16 in total

Review 1.  Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.

Authors:  David R Raleigh; Daphne A Haas-Kogan
Journal:  Future Oncol       Date:  2013-02       Impact factor: 3.404

Review 2.  Advances in non-surgical management of primary liver cancer.

Authors:  Xiao Chen; Hai-Peng Liu; Mei Li; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

3.  Growth arrest and apoptosis of human hepatocellular carcinoma cells induced by hexamethylene bisacetamide.

Authors:  Gao-Liang Ouyang; Qiu-Feng Cai; Min Liu; Rui-Chuan Chen; Zhi Huang; Rui-Sheng Jiang; Fu Chen; Shui-Gen Hong; Shi-Deng Bao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

4.  Effect of staurosporine on cycle of human gastric cancer cells.

Authors:  Min-Wen Ha; Ke-Zuo Hou; Yun-Peng Liu; Yuan Yuan
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

5.  The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Shyh-An Yeh; Yaw-Sen Chen; Daw-Shyong Perng
Journal:  J Radiat Res       Date:  2014-11-19       Impact factor: 2.724

6.  Hyperthermia-induced radiosensitization in CHO wild-type, NHEJ repair mutant and HR repair mutant following proton and carbon-ion exposure.

Authors:  Junko Maeda; Yoshihiro Fujii; Hiroshi Fujisawa; Hirokazu Hirakawa; Ian M Cartwright; Mitsuru Uesaka; Hisashi Kitamura; Akira Fujimori; Takamitsu A Kato
Journal:  Oncol Lett       Date:  2015-09-21       Impact factor: 2.967

7.  Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram.

Authors:  Xiaojie Li; Zhimin Ye; Sheng Lin; Haowen Pang
Journal:  BMC Cancer       Date:  2021-06-15       Impact factor: 4.430

8.  Synthesis of novel galactose functionalized gold nanoparticles and its radiosensitizing mechanism.

Authors:  Chuan-Dong Zhu; Qin Zheng; Li-Xue Wang; Han-Feng Xu; Jin-Long Tong; Quan-An Zhang; Yuan Wan; Jian-Qing Wu
Journal:  J Nanobiotechnology       Date:  2015-10-09       Impact factor: 10.435

9.  KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.

Authors:  Min-Bin Chen; Zhen-Tao Zhou; Lan Yang; Mu-Xin Wei; Min Tang; Ting-Yan Ruan; Jun-Ying Xu; Xiao-Zhong Zhou; Gang Chen; Pei-Hua Lu
Journal:  Oncotarget       Date:  2016-03-29

10.  Efficacy of three-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Fei-Xiang Wu; Hui-Rong Lu; Shao-Liang Zhu; Zi-Hui Li; Ling Zou; Tao Bai; Jie Chen; Tian-Bo Yang; Shi-Xiong Liang
Journal:  Onco Targets Ther       Date:  2016-12-01       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.